Recently there has been a drive from various stakeholders involved in how new medicines or medical devices gain access to the UK market to introduce changes that reflects modern needs of the country. This drive for change generated discussions and some recommendations on how National Institute for Health and Care Excellence should operate in the…

Recently there has been a drive from various stakeholders involved in how new medicines or medical devices gain access to the UK market to introduce changes that reflects modern needs of the country. This drive for change generated discussions and some recommendations on how National Institute for Health and Care Excellence should operate in the…

Today we learn that treatment for other rare diseases were approved for cystic fibrosis in Scotland and Batten disease. Thoughts and congratulations go out to everyone affected by or working hard to receive treatment for these diseases from TreatSMA.

Today we learn that treatment for other rare diseases were approved for cystic fibrosis in Scotland and Batten disease. Thoughts and congratulations go out to everyone affected by or working hard to receive treatment for these diseases from TreatSMA.

Acaster Lloyd Consulting Ltd, an independent research consultancy specialising in patient research, on behalf of a pharmaceutical company, is conducting an online survey for adults and caregivers of children with a medical diagnosis of spinal muscular atrophy (SMA) to understand views about the importance of different aspects of treatment for SMA and need your help.

Acaster Lloyd Consulting Ltd, an independent research consultancy specialising in patient research, on behalf of a pharmaceutical company, is conducting an online survey for adults and caregivers of children with a medical diagnosis of spinal muscular atrophy (SMA) to understand views about the importance of different aspects of treatment for SMA and need your help.

Now that the MAA has been released attention turns towards monitoring progress with regards to the implementation of treatment for those currently eligible. Eligible patients should have access to treatment within 90 days of the NICE guidance being released subject to any clinical or commissioning issues. This is what we know so far.

Now that the MAA has been released attention turns towards monitoring progress with regards to the implementation of treatment for those currently eligible. Eligible patients should have access to treatment within 90 days of the NICE guidance being released subject to any clinical or commissioning issues. This is what we know so far.